Great Lakes Advisors LLC Invests $2.98 Million in Prestige Consumer Healthcare Inc. $PBH

Great Lakes Advisors LLC acquired a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 63,058 shares of the company’s stock, valued at approximately $2,981,000.

Other hedge funds have also made changes to their positions in the company. UMB Bank n.a. grew its holdings in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $29,000. Geneos Wealth Management Inc. lifted its position in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the period. Torren Management LLC acquired a new stake in Prestige Consumer Healthcare during the fourth quarter worth $35,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after buying an additional 236 shares during the period. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PBH. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Stock Down 2.1%

PBH opened at $50.59 on Friday. The firm’s 50-day simple moving average is $49.65 and its 200-day simple moving average is $55.14. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $71.07. The firm has a market cap of $2.40 billion, a price-to-earnings ratio of 14.17, a PEG ratio of 1.62 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).